Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth

Prostate

Volumn 72, Issue 3, 2012, Pages 244-252

  Yan, Jun ^a,b   Xie, Bingxian ^a   Capodice, Jillian L ^b   Katz, Aaron E ^b  

^a NANJING UNIVERSITY   (China)

^b Department of Medicine   (United States)

Author keywords

chemoprevention; herb; prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC ALKALOID; BICALUTAMIDE; CASPASE 3; LUCIFERASE; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; PROTEIN BCL XL; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NKX3.1; UNCLASSIFIED DRUG; ZYFLAMEND;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN LNCAP; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HORMONE RESPONSE; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADENOCARCINOMA; ANDROGEN RECEPTOR ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG SYNERGISM; HOMEODOMAIN PROTEINS; HUMANS; MALE; NITRILES; PLANT EXTRACTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA, MESSENGER; SIGNAL TRANSDUCTION; TOSYL COMPOUNDS; TRANSCRIPTION FACTORS;

EID: 84855672956     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21426     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics. CA Cancer J Clin 2009; 59: 225-249.
2. Isaacs WB, Bova GS, Morton RA, Bussemakers MJ, Brooks JD, Ewing CM,. Molecular biology of prostate cancer progression. Cancer Surv 1995; 23: 19-32.
3. Heemers HV, Tindall DJ,. Androgen receptor (AR) coregulators: A diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 2007; 28: 778-808. (Pubitemid 350294296)
4. Slagsvold T, Kraus I, Frønsdal K, Saatcioglu F,. DNA binding-independent transcriptional activation by the androgen receptor through triggering of coactivators. J Biol Chem 2001; 276: 31030-31036. (Pubitemid 37384967)
5. Yan J, Erdem H, Li R, Cai Y, Ayala G, Ittmann M, Yu-Lee LY, Tsai SY, Tsai MJ,. Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression. Cancer Res 2008; 68: 5460-5468.
6. Debes JD, Tindall DJ,. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004; 351: 1488-1490. (Pubitemid 39315314)
7. Thompson IM, Tangen CM, Goodman PJ, Lucia MS, Klein EA,. Chemoprevention of prostate cancer. J Urol 2009; 182: 499-507.
8. Reed AB, Parekh DJ,. The utility of 5-alpha reductase inhibitors in the prevention and diagnosis of prostate cancer. Curr Opin Urol 2009; 19: 238-242.
9. Andriole GL,. Overview of pivotal studies for prostate cancer risk reduction, past and present. Urology 2009; 73 (5 Suppl.): S36-S43.
10. Litvinov IV, De Marzo AM, Isaacs JT,. Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab 2003; 88: 2972-2982. (Pubitemid 36877458)
11. Bemis DL, Capodice JL, Anastasiadis AG, Katz AE, Buttyan R,. Zyflamend, a unique herbal preparation with nonselective COX inhibitory activity, induces apoptosis of prostate cancer cells that lack COX-2 expression. Nutr Cancer 2005; 52 (2): 202-212. (Pubitemid 41579762)
12. Yang P, Cartwright C, Chan D, Vijjeswarapu M, Ding J, Newman RA,. Zyflamend-mediated inhibition of human prostate cancer PC3 cell proliferation: Effects on 12-LOX and Rb protein phosphorylation. Cancer Biol Ther 2007; 6: 228-236. (Pubitemid 46641627)
13. Yang P, Sun Z, Chan D, Cartwright CA, Vijjeswarapu M, Ding J, Chen X, Newman RA,. Zyflamend reduces LTB4 formation and prevents oral carcinogenesis in a 7,12-dimethylbenz[alpha] anthracene (DMBA)-induced hamster cheek pouch model. Carcinogenesis 2008; 29: 2182-2189.
14. Capodice JL, Gorroochurn P, Cammack S, Eric G, McKiernan JM, Benson MC, Stone BA, Katz AE,. Zyflamend in men with high-grade prostatic intraepithelial neoplasia: Results of a phase I clinical trial. J Soc Integr Oncol 2009; 7: 43-51.
15. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, Bova GS, Luo J,. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009; 69: 16-22.
16. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ,. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008; 68: 5469-5477.
17. Eastham JA,. Prostate-specific antigen doubling time as a prognostic marker in prostate cancer. Nat Clin Pract Urol 2005; 2: 482-491. (Pubitemid 41594402)
18. Jones SB, DePrimo SE, Whitfield ML, Brooks JD,. Resveratrol-induced gene expression profiles in human prostate cancer cells. Cancer Epidemiol Biomarkers Prev 2005; 14: 596-604. (Pubitemid 40489201)
19. Harada N, Murata Y, Yamaji R, Miura T, Inui H, Nakano Y,. Resveratrol down-regulates the androgen receptor at the post-translational level in prostate cancer cells. J Nutr Sci Vitaminol (Tokyo) 2007; 53: 556-560. (Pubitemid 351154880)
20. Shi WF, Leong M, Cho E, Farrell J, Chen HC, Tian J, Zhang D,. Repressive effects of resveratrol on androgen receptor transcriptional activity. PLoS One 2009; 4: e7398.
21. Wang TT, Hudson TS, Wang TC, Remsberg CM, Davies NM, Takahashi Y, Kim YS, Seifried H, Vinyard BT, Perkins SN, Hursting SD,. Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivo. Carcinogenesis 2008; 29: 2001-2010.
22. Harper CE, Patel BB, Wang J, Eltoum IA, Lamartiniere CA,. Epigallocatechin-3-Gallate suppresses early stage, but not late stage prostate cancer in TRAMP mice: Mechanisms of action. Prostate 2007; 67: 1576-1589. (Pubitemid 47536156)
23. Nakamura K, Yasunaga Y, Segawa T, Ko D, Moul JW, Srivastava S, Rhim JS,. Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines. Int J Oncol 2002; 21: 825-830.
24. Zhang HN, Yu CX, Zhang PJ, Chen WW, Jiang AL, Kong F, Deng JT, Zhang JY, Young CY,. Curcumin downregulates homeobox gene NKX3.1 in prostate cancer cell LNCaP. Acta Pharmacol Sin 2007; 28: 423-430.
25. Ju Q, in XP, Shi JH, Kang XJ, Xin Y, Xia LQ,. Effects of baicalin and other Chinese herbal monomer on androgen receptor mRNA expression in SZ95 sebocytes. Zhongguo Yi ue Ke Xue Yuan Xue Bao 2007; 29: 167-170. (Pubitemid 46839487)
26. Narayanan NK, Nargi D, Randolph C, Narayanan B,. Liposome encapsulation of curcumin and resveratrol in PTEN knockout mice. Int J Cancer 2009; 125: 1-8.